A multi-center and non-interventional registry of Brentuximab Vedotin in patients with relapsed or refractory anaplastic large cell lymphoma or classical Hodgkin lymphoma
Not Applicable
Recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0003789
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
1) Any patient planning to administer BrentuximabVedotin to treat the target disease.
2) Any patient administering BrentuximabVedotin to treat the target disease.
3) Any patient tracing BrentuximabVedotin after treating the target disease.
4) Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin
Exclusion Criteria
If conditions for target diseases are not met.
If conditions for target patients are not met.
If patients do not give written consent to participate in study.
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall response rate
- Secondary Outcome Measures
Name Time Method Response retention period;Survival with no therapy;Overall survival period;Length of time until next treatment